Actively Recruiting
Comparing Vonorasan and Esomeprazole with Aluminum Phosphate Gel for Treating Ulcers After Endoscopic Submucosal Dissection
Led by Shicai Ye · Updated on 2026-11-02
196
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This clinical trial evaluates the effectiveness and safety of voronasan combined with aluminum phosphate gel compared to esomeprazole combined with aluminum phosphate gel in treating post-operative ulcers after Endoscopic Submucosal Dissection ESD. The study aims to determine whether voronasan with aluminum phosphate gel is clinically more effective and to identify any medical issues participants may experience with this combination therapy. Participants receive intravenous lansoprazole for 1 to 3 days after ESD, followed by oral treatment with either voronasan 20 mg tablets once daily or esomeprazole 20 mg tablets from day 3 to day 56 after ESD. Both treatments are combined with aluminum phosphate gel. The trial uses a randomized, double-blind, parallel design to compare these treatments over this period. During the study, participants will record their symptoms and undergo evaluations of ulcer grading and size through endoscopy. Researchers will calculate ulcer healing rates and assess ulcer reduction at weeks 2 and 8 after starting treatment. Safety and postoperative symptom relief are also monitored throughout the study duration, which lasts up to 8 weeks post-dose.
CONDITIONS
Brief Title
Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection
Research Team
S
Shicai Ye, PhD
Y
Yuping Yang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here